2018 - Nanbiosis

JUMISC OBTAINS TWO INTERNATIONAL RECOGNITIONS AT THE ANNUAL MEETING OF THE LAPAROSCOPIC SURGEONS SOCIETY HELD IN NEW YORK

Dr. Francisco Miguel Sánchez Margallo, Assistant Director of NANBIOSIS and Scientific Director of JUMISC, has attended the multidisciplinary Congress organized by the Society of Laparoendoscopic Surgeons (SLS), held in New York from August 29 to September 1, where he has presented scientific communications with very innovative results in the specialty of urology.

At the annual meeting of this Scientific Society, international specialists related to minimally invasive surgery meet, with the aim of increasing knowledge of laparoscopic, endoscopic and minimally invasive surgical techniques, including robotic surgery.

The papers presented by Dr. Francisco M. Sánchez Margallo, have received the Harrith M. Hasson Award for the best oral communication, for promoting Teaching and Training in the specialty of urology. He has received this award from the wife of Dr. Hasson, one of the pioneers in laparoscopic surgery and inventor of the open laparoscopic technique and the trocar that bears his name.

The objectives of this work are focused on developing a platform for training and surgical assistance in urology, based on mixed reality technology. In addition, an application with this technology is incorporated for viewing, in real time, by surgeons of tomography, resonance and three-dimensional models of patients.

The results of this work have been tested by different experts of the Spanish Association of Urology (AEU) in the operating rooms of the Center, through an application that allows viewing, in real time, the preoperative studies of tomography, resonance and a human pelvic model. in 3D, through a recreation in the Hololens mixed reality glasses, marketed by the Microsoft company.

The second of the papers presented by Dr. Sánchez Margallo has received a mention of scientific honor, showing the results of the analysis of surgical skills and ergonomic studies of surgeons during the use of a novel robotic device in laparoscopic urological surgery.

These studies have involved different professionals from the clinical and technological areas of the Center and collaborators of the Biomechanics group of the University of Extremadura (UEX) and the CIBEX technology company, in addition to the advice of various Spanish urologists.

The Jesús Usón Minimally Invasive Surgery Center Foundation is a unique infrastructure that works in research, training and innovation in the health field.

• Read More

A new pathway for the prevention of metastasis in colorectal cancer in humans is open: a nanomedicine that selectively eliminates metastatic stem cells

Researchers of NANBIOSIS U18 Nanotoxicology Unit and U1. Protein Production Platform (PPP) at the Biomedical Research Institute of Sant Pau (IIB Sant Pau), of the Hospital of Santa Creu i Sant Pau, of the Universitat Autònoma de Barcelona (UAB), the Superior Council of Scientific Research (CSIC) and the Center for Biomedical Research in Network (CIBER) have published an article in one of the most prestigious international scientific journals in the field of Molecular Medicine, EMBO Molecular Medicine. This article demonstrates the efficacy of the nanopharmaceutical that selectively removes metastatic stem cells in animal models of colon cancer. The new drug works like a drone that has a ligand that identifies a receptor (CXCR4) in the metastatic stem cells, administers the drug and destroys these cells by blocking the metastasis. The drug acts only on metastatic tumor cells and not on healthy cells, so it avoids the general toxicity associated with the usual treatments

This nanopharmaceutical has been successfully tested in animal models of colorectal cancer, but could be used in 20 additional tumor types that express CXCR4,
as in those of prostate, breast, ovary and others

This is the first drug in the world selectively antimetastatic that addresses the medical need to block metastatic spread, the main cause of death in cancer patients, while eliminating the toxicity and adverse effects of conventional treatments

The Hospital de Sant Pau could be the first center in the world to carry out clinical trials that evaluate this new drug in patients, prior to its possible introduction in clinical therapeutics

It has been observed that this receptor is overexpressed in at least 20 different types of cancer, including those of the prostate, breast, ovary and others not as common as the pancreas. This means that this nanoparticle can be targeted to treat different types of neoplasms, making it a very versatile vehicle that can transport different therapeutic molecules of high potency.

Article of reference:

María Virtudes Céspedes, Ugutz Unzueta, Anna Aviñó, Alberto Gallardo, Patricia Álamo, Rita Sala, Alejandro Sánchez‐Chardi, Isolda Casanova, María Antònia Mangues, Antonio Lopez‐Pousa,Ramón Eritja, View Antonio Villaverde, Esther Vázquez, Ramón Mangues. Selective depletion of metastatic stem cells as therapy for human colorectal cancer. EMBO Molecular Medicine (2018) e8772 Published online 06.09.2018. DOI 10.15252/emmm.201708772

The team of researchers, led by Dr. Ramón Magues de l’IIB Sant Pau, Prof. Antonio Villaverde of the UAB and Dr. Esther Vázquez of the UAB, have shown that the drug acts only on metastasis-initiating cells through its specific interaction between a peptide present in the protein nanoparticle that transports it and the cellular receptor CXCR4 that is overexpressed in tumor cells. This allows attacking only the tumor cells, blocking their dissemination in early stages, in a way that prevents the appearance of metastasis while avoiding the adverse effects derived from the usual treatments.

Nanoligent, a new spin-off to finance the nanoparticle

In June 2017, researchers from the IIB Sant Pau, from the Institute of Biotechnology and Biomedicine of the UAB and the CIBER from Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) who signed the article published now in EMBO Molecular Medicine created a spin-off, Nanoligent , with the aspiration to develop the first drug designed to eliminate metastatic cells.

This company, which has more than 10 years of studies behind it, is directed by Dr. Manuel Rodríguez Mariscal, a professional with a long experience in the field of investment and the creation of biotechnology companies and aims to obtain financing for the realization of the project.

• Read More

NANBIOSIS Unit 27 at VPH2018: VIRTUAL PHYSIOLOGICAL HUMAN 2018

The VPH Conference 2018 is taking place in Zaragoza 5-7 September offering an exciting program of state-of-the art science & engineering in computational (bio)medicine, ranging from foundational research on multiscale modelling of human (patho) physiology, via underpinning research on data science and infrastructures for the virtual physiological human, to clinical applications with participation of NANBIOSIS U27. High Performance Computing

Esther Pueyo is charing the Session 3A: Cardiovascular modeling: from simulation to clinical outcome,

Some of the outcomes are presented by Jesús Fernández-Bes :

A Bayesian Filtering methodology to identify key drivers of ventricular repolarization variability (Jesus Fernandez-Bes, David Adolfo Sampedro-Puente and Esther Pueyo)

Virtual Physiological Human (VPH), refers to the field of integrative mathematical modelling and simulations in the study of human biology and physiology. VPH is a methodological and technological framework to share observations, to derive predictive hypotheses from possible aspects of human physiology or pathology, and to integrate them into a constantly improving understanding of human physiology and pathology, by regarding it as a single system. Currently, the VPH is a worldwide effort to develop next-generation computer technologies to integrate all information available, from genetics to medical images to clinical data for each patient, and generate computer models capable of predicting how the health of that patient will evolve under certain conditions. The VPH is now a well-established worldwide community, with the VPH institute representing it.

• Read More

Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma

As a result of the collaboration carried aout by two units of NANBIOSIS, U4. Biodeposition and Biodetection Unit and U2. Custom Antibody Service (CAbS), it has been developed a compact and simple nanoplasmonic sensing device based on gold nanodisks for the rapid monitoring of acenocoumarol, using highly specific polyclonal antibodies produced against the drug Acenocoumarol (Sintrom®) which implies:

A label-free nanoplasmonic device for the rapid monitoring of acenocoumarol in plasmaD.
Direct quantification in real time requiring low sample volume is achieved.
Non-specific interferences from plasma are minimized using the developed methodology.
Excellent accuracy has been observed measuring blind plasma samples.
Potential to be implemented as a POC device in decentralized settings.

The research details have been published in the article authored by E. CristinaPeláez, M.-CarmenEstevez, AlejandroPortela, J.-PabloSalvador, M.-PilarMarco and Laura M.Lechuga, “Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma, Biosensors and Bioelectronic, 119, 2018, 149-155 – DOI: https://doi.org/10.1016/j.bios.2018.08.011

• Read More

COURSE FOR THE PERFORMANCE OF FUNCTIONS A, B AND C IN RODENTS, LAGOMORFOS, CARNIVORES, PIGS AND SMALL RUMINANTS

On November 2th-30th, Centro de Cirugía de Mínima Invasión Jesús Usón, partner of NANBIOSIS, organizes a theorical and practical course: “Course for the performance of functions a, b and c in rodents, lagomorfos, carnivores, pigs and small ruminants”. Some researchers of NANBIOSIS Units at JUMISC, will transmit their knowhow and experience to the attendees.

The course objetives are to provide adequate training to researchers in the science and welfare of the laboratory animal, as well as the use of bloodless methods of euthanasia that will be carried out with experimental animals in accordance with current legislation and existing recommendations.

This course, once met all the requirements demanded by the Competent Authority (supervised work period) by the students, will provide accreditation for the performance of FUNCTIONS A (care of animals), B (euthanasia of animals) and C (realization of procedures), granted by the Ministry of Environment and Rural, Agrarian Policies and Territory. These functions correspond to those established in article 15, point 2 letters a), b) and c) of Royal Decree 53/2013, of February 1, which establishes the basic rules applicable for the protection of animals used in experimentation and other scientific purposes, including teaching

Program

Inscription

• Read More

Recombinant proteins production: optimization strategies.

On October 24th-26th, Aula Científica, in collaboration with IBB, organizes a theorical and practical course on “Recombinant proteins production: optimization strategies“. Some researchers of NANBIOSIS Unit1 Protein Production Platform (PPP), will transmit their knowhow and experience to the attendees, as José Luis Corchero, Rosa Mendoza Moreno and Neus Ferrer Miralles, Scientific Director of the Protein production planform of ICTS NANBIOSIS.

The course is aimed at researchers and laboratory technicians from universities, hospitals, companies and research centers who are interested in the expression, production and purification of recombinant proteins with de objectives of analyze and design strategies for the improvement in the expression, production and purification of recombinant proteins in heterologous systems.

Information and registration:

• Read More

Nanbiosis

You are here : Home / 2018 (Page 4)

JUMISC OBTAINS TWO INTERNATIONAL RECOGNITIONS AT THE ANNUAL MEETING OF THE LAPAROSCOPIC SURGEONS SOCIETY HELD IN NEW YORK

A new pathway for the prevention of metastasis in colorectal cancer in humans is open: a nanomedicine that selectively eliminates metastatic stem cells

NANBIOSIS Unit 27 at VPH2018: VIRTUAL PHYSIOLOGICAL HUMAN 2018

Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma

COURSE FOR THE PERFORMANCE OF FUNCTIONS A, B AND C IN RODENTS, LAGOMORFOS, CARNIVORES, PIGS AND SMALL RUMINANTS

Recombinant proteins production: optimization strategies.

Conversion of Biomolecules into pharmaceuticas Leads using nanovesicles

Peptides, targeting units and drug conjugates

Advanced methods of continuous production of Nanomaterials

Micro and nanotechnologies for the release of biotechnological products